Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Chemotherapy for Relapsed Germ-Cell Tumors
NCT00936936Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2009
- Primary completion
- Jan 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, docetaxel, melphalan, carboplatin, ifosfamide and 1 more in germ cell tumor (GCT), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Event-Free Survival at 2 years. Started Jun 2009; status: completed.
02
Drugs
gemcitabinedocetaxelmelphalancarboplatinifosfamide
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT00936936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00936936.